Preoperative Intravesical Electromotive Mitomycin-c for Primary Non-muscle Invasive Bladder Cancer

Single Preoperative Intravesical Instillation of Electromotive Mitomycin-c for Primary Non-muscle Invasive Bladder Cancer: a Prospective Randomized Trial.

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01149174

Acronym

EMDA/PRE-TUR

Enrollment

352

Registered

2010-06-23

Start date

1994-01-31

Completion date

2009-06-30

Last updated

2011-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Superficial Bladder Cancer

Keywords

intravesical chemotherapy, early single instillation, mitomycin-C, electromotive drug administration

Brief summary

Early single instillation of chemotherapy after TUR is recommended in the European Association of Urology Guidelines. Nevertheless, the procedure is suboptimal for patients with multiple tumors, sometimes is not tolerated and it can results in severe complications. In both laboratory and clinical studies, intravesical electromotive drug administration (EMDA) increases mitomycin-C (MMC) bladder uptake, resulting in an improved clinical efficacy in non-muscle invasive bladder cancer (NMIBC). The investigators will compare the effects of one immediate pre-TUR intravesical EMDA/MMC instillation with one immediate post-TUR intravesical passive diffusion MMC (PD/MMC) instillation and TUR alone in patients with NMIBC. All eligible patients with primary NMIBC will be randomized into 3 groups who will undergo transurethral resection alone (TUR/alone); TUR plus single immediate postoperative instillation (immediately after TUR) of 40 mg PD/MMC with a dwell time of 60 minutes; or single immediate preoperative instillation (immediately before TUR) of 40 mg EMDA/MMC with 20 mA electric current for 30 minutes. Patients with intermediate and high risk NMIBC will undergo adjuvant intravesical therapy. The primary end points will be the recurrence rate and disease-free interval. All clinical analyses will be performed on an intent to treat basis.

Interventions

DRUGMitomycin-C 40 mg

Intravesical instillation of Mitomycin-C

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

* All patients with primary histologically proven stage pTa-pT1 transitional-cell carcinoma of the bladder

Exclusion criteria

* Previous treatments with bacillus Calmette-Guerin, mitomycin-C, or with any other intravesical cytostatic agent * Concomitant urothelial tumours of the upper urinary tract * Previous or concomitant muscle-invasive (ie, stage T2 or higher) transitional-cell carcinoma of the bladder * Bladder capacity less than 200 ml * Untreated urinary-tract infection * Disease of upper urinary tract * Previous radiotherapy to the pelvis * Other concurrent chemotherapy * Treatment with radiotherapy-response or biological-response modifiers * Other malignant diseases within 5 years of trial registration (except for basal-cell carcinoma) * Pregnancy or nursing * And psychological, familial or sociological factors that would preclude study participation

Design outcomes

Primary

Measure	Time frame
disease-free interval and recurrence rate	recurrence assessed at 1 and 3 years from randomisation

Secondary

Measure	Time frame
disease progression and overall and specific disease mortality	progression and mortality assessed at 5 years from randomisation

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 28, 2026